Skip to content
lifestyle.fairytaleinkbooks.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Rapport Therapeutics, Inc.
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Mania
October 20, 2026
Rapport Therapeutics to Participate in Upcoming Investor Conferences
September 2, 2026
Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program
August 24, 2026
Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update
August 5, 2026
Rapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference
May 20, 2026
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
May 8, 2026
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
March 9, 2026